NovaGold Q3 2026 earnings widen to loss of $36 million
Bitget2026/10/08 12:03NovaGold posted earnings of USD -36 million, or USD -0.08 a share, for the quarter ended Aug. 31, 2026. Net third-quarter operational cash expenditures rose to USD 28.1 million, including USD 24.8 million for Donlin Gold and USD 3.3 million corporate costs. Cash and term deposits fell to USD 343.39 million as of Aug. 31, 2026, while total assets edged down to USD 573.29 million. Donlin Gold’s BFS stayed on track for completion in 2027, with Fluor integrating engineering work and a Class 3 estimate underway. NovaGold agreed to acquire Paulson’s 40% stake in Donlin Gold in an all-share deal, lifting ownership to 100%, expected by year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaGold Resources Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9841706) on October 08, 2026, and is solely responsible for the information contained therein.
- NovaGold posted earnings of USD -36 million, or USD -0.08 a share, for the quarter ended Aug. 31, 2026.
- Net third-quarter operational cash expenditures rose to USD 28.1 million, including USD 24.8 million for Donlin Gold and USD 3.3 million corporate costs.
- Cash and term deposits fell to USD 343.39 million as of Aug. 31, 2026, while total assets edged down to USD 573.29 million.
- Donlin Gold’s BFS stayed on track for completion in 2027, with Fluor integrating engineering work and a Class 3 estimate underway.
- NovaGold agreed to acquire Paulson’s 40% stake in Donlin Gold in an all-share deal, lifting ownership to 100%, expected by year-end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
